In this pragmatic long-term follow-up of the SPRINT randomized trial cohort, rates of recurrent stroke and all-cause mortality did not differ significantly by an initial fixed low- versus moderate-dose of hydroxyurea over 4.9 years, with events clustering in the first year.
No takes yet. Share an insight, caveat, or question.
Iguda et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: